Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IPILIMUMAB Cause Electrocardiogram qt prolonged? 27 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 27 reports of Electrocardiogram qt prolonged have been filed in association with IPILIMUMAB (YERVOY). This represents 0.1% of all adverse event reports for IPILIMUMAB.

27
Reports of Electrocardiogram qt prolonged with IPILIMUMAB
0.1%
of all IPILIMUMAB reports
3
Deaths
20
Hospitalizations

How Dangerous Is Electrocardiogram qt prolonged From IPILIMUMAB?

Of the 27 reports, 3 (11.1%) resulted in death, 20 (74.1%) required hospitalization, and 1 (3.7%) were considered life-threatening.

Is Electrocardiogram qt prolonged Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IPILIMUMAB. However, 27 reports have been filed with the FAERS database.

What Other Side Effects Does IPILIMUMAB Cause?

Death (3,710) Malignant neoplasm progression (3,296) Diarrhoea (2,557) Off label use (2,097) Colitis (1,988) Pyrexia (1,796) Rash (1,556) Fatigue (1,447) Intentional product use issue (1,329) Nausea (1,169)

What Other Drugs Cause Electrocardiogram qt prolonged?

QUETIAPINE (1,869) OLANZAPINE (1,325) RIBOCICLIB (1,020) AMIODARONE (1,000) HYDROXYCHLOROQUINE (992) CLOZAPINE (958) CITALOPRAM HYDROBROMIDE (917) ESCITALOPRAM OXALATE (899) ONDANSETRON (881) BUPROPION (853)

Which IPILIMUMAB Alternatives Have Lower Electrocardiogram qt prolonged Risk?

IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE IPILIMUMAB vs IPRATROPIUM IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS IPILIMUMAB vs IPTACOPAN IPILIMUMAB vs IRBESARTAN

Related Pages

IPILIMUMAB Full Profile All Electrocardiogram qt prolonged Reports All Drugs Causing Electrocardiogram qt prolonged IPILIMUMAB Demographics